drugset

drugset / Trial / NCT01215279

AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)

NCT01215279 ↗

Phase 2 Completed 63 enrolled AstraZeneca

RandomizedParallel-groupTriple-blindBasic science

Summary

The purpose of the study is to investigate the tolerability and safety of AZD2423 in Patients with chronic obstructive pulmonary disease.

Timeline

Start: 2010-10
Primary completion: 2011-03
Completion: 2011-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD2423	Unknown	100 mg	Oral

Indications